borrowing from Daydreaming2, below is what i poste

borrowing from Daydreaming2, below is what i posted on the other board.... lots of stuff upcoming. time to hold the line imo.

//

1) UPCOMING MILESTONES / CATALYSTS

SCIENCE

- Start of B-ABSSSI (Phase 3) (With Fast-Track designation, per QIDP)
- Completion of K (Phase 1) (more dets as to safety, efficacy)
- Initiation of several K phase 2, 2/3 trials (ovarian, pancreatic, AML) (more frequent dosing likely, grant support--addtl Orphan designation/s)
- Meeting w / FDA on K-pediatric retinoblastoma (rare disease)
- Phase 2 B-OM update
- Phase 2 P update/completion
- ABX platform -- progress on anti-fungals, anti-biofilm (MTA signed for B-prophylactic testing), gram-neg compounds; GI targets (Chrons, IBD, H Supportiva)

OPERATIONS

- Financing in place (shelf, Aspire)
- 1st Shareholder meeting (Dec 15... Be it pitchfork or rose petal in feel)
- NASDAQ uplisting (if $2 is maintained)
- Class Action Defense (Legal)
- Partners: still think this is likely farther off... Post Ph III ABSSSI for ABX... And will it be by indication or for whole platform? Kevetrin, the wildcard... As a case study, see CELG-Nurix deal (p53)

https://blogs.shu.edu/cancer/2015/09/30/ubiqu...d-celgene/

2) CURRENT TRIALS

Clinical Trials

Overall - https://clinicaltrials.gov/ct2/results?term=c...rch=Search

1. P (Phase 2, recruiting): https://clinicaltrials.gov/ct2/show/NCT024944...amp;rank=1

2. B-OM (Phase 2, recruiting): https://clinicaltrials.gov/ct2/show/NCT023243...amp;rank=3

3. K (Phase 1, recruiting): https://clinicaltrials.gov/ct2/show/NCT016640...amp;rank=4

4. B-ABSSSI (Phase 2, completed): https://clinicaltrials.gov/ct2/show/NCT020523...amp;rank=5

Abbreviations

K – Kevetrin
B – Brilacidin
P – Prurisol
OM – oral mucositis
ABSSSI – acute bacterial skin and skin structure infections
QIDP – qualified infectious disease product

Company Website:
cellceutix.com